Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
Recruiting · NCT07286292 · Registry updated 2026-09-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation | Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation | Recruiting | Phase 2 | 2026-09-08 | NCT07286292 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Institut de Recherches Internationales Servier (I.R.I.S.) | 4 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Children's Minnesota | Minneapolis | United States | 13 |
| Dana Farber (DFCI) | Boston | United States | 1 |
| Kids Cancer Centre, Sydney Children's Hospital Randwick | Sydney | Australia | 1 |
| Lurie Children' sNWU | Chicago | United States | 1 |
| UCLA | Los Angeles | United States | 80 |